Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000 percent.

UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that competition in the space could limit upside. The note also said investors likely want to see longer-term durability data, with limited near-term catalysts, before topline data from the BEACON Phase 2b study in chronic spontaneous urticaria, or CSU, expected in 2027.

Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab

The call came after Jasper had already reported updated data for briquilimab on January 8. The company said 67% of additional patients treated with briquilimab in the BEACON Phase 1b/2a study achieved a complete response at 12 weeks, while 83% achieved a complete response by week 3 after the initial dose. Jasper also said the BEACON and open-label extension data were enough to support dose selection for a Phase 2b study in CSU planned to begin in the second half of 2026.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company developing briquilimab, an antibody therapy targeting KIT (CD117), for mast cell-driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.

While we acknowledge the risk and potential of JSPR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JSPR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.